CPhI Pharmaceutical Machinery Report: Investment is key

The changing drugs pipeline and the industry's drive towards more efficient manufacturing define the use of modern equipment

P-MEC, the only dedicated pharmaceutical machinery event in Europe, will be co-located with CPhI Worldwide in Frankfurt this year. The event has published the first-ever CPhI Pharmaceutical Machinery Report, identifying trends and highlighting how the changing drugs pipeline and the industry's drive towards more efficient manufacturing is necessitating new investments in pharma equipment.

A changing tune

The evolving R&D pipeline of smaller volume drugs, coupled with advanced technologies that remove scale-up challenges - such as single-use equipment and continuous processing - are not only transforming industry attrition rates, but vastly changing the types of machinery used in pharma manufacturing. Moreover, running alongside this pipeline evolution are newer approaches that reduce the number of steps in process development, making production greener and lowering overall cost.

Manufacturing is now at a crucial juncture as push and pull drivers - including newer technologies, changing pipelines and demand for lower-cost drugs - combine to significantly alter how drugs will be made in the future. The report predicts we are on the cusp of a new age of smart pharma manufacturing, as equipment is set to take centre-stage in the development of advanced medicines.

P-MEC 2019 itself is a testament to this trend. Exhibitor numbers have doubled in a single year to over 150, as the industry shifts its perspective on new technologies from "in an ideal world we would" to "we must have these to grow".

In an industry that has often been dependent on legacy systems and undertaking manufacturing in "the same way as before" for fear of encountering any potential regulatory hurdles, this is a seismic shift. Significantly, this potentially has huge implications for the entire supply chain and CPhI Worldwide is seeing changes across all parts of the show from contract services to ingredients, packaging and finished dosage drugs.

Trending up

The report also forecasts how flexibility in product design is now integral to the lifespan of equipment - a consequence of new products often being produced for smaller patient cohorts. For example, new types of delivery systems and dosages, mean new packaging and labelling equipment are needed that can adjust to these individual dosage forms.

Reflecting industry drivers, the agenda at P-MEC 2019 explores the implications of patient centricity, evolving equipment for an eco-friendly age, and how new devices used in the biologics industry are affecting equipment considerations and the implications for filling machines.

In another key trend, regulators are striving to make manufacturing processes increasingly standardised and controlled - with technologies that improve quality risk-based methodologies (QRM), Quality by Design (QbD), process analytical technology (PAT) and continuous manufacturing encouraged.

A potential implication of seeking greater control in process methods will be the need for an increased use of real-time monitoring. Significantly, methods from raman and infrared spectroscopy, chromatographic separation to faster technologies such as ultra-performance liquid chromatography (UPLC) or ultra-high performance LC (UHPLC) are proliferating alongside nuclear magnetic resonance (NMR). However, the big challenge that continues to remain is how to build these into commercial production for real-time analysis in enclosed systems, single-use technologies, and continuous rigs.

Finally, the report ponders how digital technologies may improve production and machinery as an "unknown variable". For example, the impact that digital technologies will play in reducing downtime and increasing process efficiency through AI. One solution could see the use of connected machines to reduce the need for pharma customers to audit contract manufacturers or ingredient suppliers in person - with real-time product updates supplied automatically, essentially a natural evolution of PAT guidelines.

Orhan Caglayan, Brand Director of CPhI Worldwide & P-MEC, said: "From the optimisation of old legacy manufacturing sites to the increased use of testing facilities and equipment, there is genuine excitement around the pharmaceutical machinery industry."

Companies